Trial reportJournal of clinical periodontology2026
Use of the Probiotic Limosilactobacillus reuteri as an Adjunct to Subgingival Instrumentation in the Treatment of Periodontitis Patients With Diabetes: A Randomised Clinical Trial.
Trial report in Journal of clinical periodontology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04069611 (Non Surgical Therapy of Periodontitis in Diabetes Patients), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Non Surgical Therapy of Periodontitis in Diabetes Patients: the Adjunctive Use of Probiotics
Who cites it
2 citing papers in PubMed.
- Use of the Probiotic Limosilactobacillus reuteri as an Adjunct to Subgingival Instrumentation in the Treatment of Periodontitis Patients With Diabetes: A Randomised Clinical Trial.Journal of clinical periodontology · 2026Trial
- Subgingival microbiome and adjunctive use of probiotics in the treatment of periodontitis in patients with diabetes: a secondary analysis of a randomized clinical trial.Journal of oral microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
aimTo evaluate the clinical and microbiological effects of a Limosilactobacillus reuteri-based probiotic as an adjunct to subgingival instrumentation in untreated periodontitis patients with diabetes.
methodsA 6-month, randomised, triple-blinded clinical trial was conducted involving 40 patients, receiving steps 1 and 2 of periodontal therapy, including subgingival instrumentation, and randomised to receive tablets containing L. reuteri or placebo, for 3 months. Clinical and microbiological outcomes as well as glycosylated haemoglobin (HbA1c) concentrations were evaluated at baseline and at 3 and 6 months after therapy.
resultsAt 6 months, both groups showed statistically significant reductions in the primary outcome (mean probing depth), with reductions of 0.9 mm in the probiotic group and 0.8 mm in the placebo group, with no significant differences between them. Both groups exhibited reductions in HbA1c levels after 6 months, more in the probiotic group (-0.6% vs. -0.1%), with statistically significant inter-group differences (-0.5%; 95% confidence interval [-1.0; 0.0]; p < 0.001). Microbiological outcomes were similar.
conclusionsThe adjunctive use of a L. reuteri-based probiotic did not provide additional clinical or microbiological benefits, compared to placebo, following subgingival instrumentation in patients with periodontitis and diabetes. However, statistically significant differences in HbA1c levels were observed, with larger reductions in the probiotic group, suggesting a potential systemic benefit.
trial registrationThe protocol was approved by the Clinical Research Ethics Committee (CEIC) of Hospital Clínico de San Carlos (internal code 19/101-R_X) and registered a priori in ClinicalTrials.gov (identifier NCT04069611).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.